MiMedx GroupMDXG
About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Employees: 895
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.62% more ownership
Funds ownership: 65.17% [Q2] → 66.79% (+1.62%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
6% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 63
4% less funds holding
Funds holding: 202 [Q2] → 193 (-9) [Q3]
13% less capital invested
Capital invested by funds: $667M [Q2] → $580M (-$87.2M) [Q3]
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
88% less call options, than puts
Call options by funds: $56K | Put options by funds: $484K
Research analyst outlook
We haven’t received any recent analyst ratings for MDXG.
Financial journalist opinion
Based on 3 articles about MDXG published over the past 30 days
